Relay Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 323
- Market Cap
- $955.9M
- Website
- http://www.relaytx.com
- Introduction
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Relay Therapeutics collaborates with Pfizer to evaluate a triplet combination of RLY-2608, atirmociclib, and fulvestrant in PI3Kα-mutated HR+/HER2- metastatic breast cancer patients, aiming for trial initiation by end of 2024. RLY-2608 is a mutant selective PI3Kα inhibitor, potentially benefiting over 250,000 patients annually in the U.S.
Understanding the company landscape in AI-driven biopharma R&D
AI advancements are transforming drug discovery, with tools like AlphaFold2 enhancing protein-structure prediction. Biopharma firms are building AI capabilities through in-house expertise, acquisitions, and partnerships. Despite a decline in new AI-driven biotech companies, capital deployment has surged, with significant partnerships and some clinical trial successes. However, challenges in integration and competition persist, suggesting a future of increased M&A activity and a focus on unsaturated niches like RNA-based therapeutics.
Oppenheimer Says These 2 Stocks Have Double-Digit Gains in Sight
2023 sees a shift to positive financial sentiment, with inflation improving and the Fed's rate policy gaining traction. China moves away from 'Zero COVID', aiding global economic recovery. Oppenheimer highlights Relay Therapeutics and Tyra Bioscience as strong buys, with potential for significant returns due to their innovative cancer treatments.
© Copyright 2025. All Rights Reserved by MedPath